Amphiphysin Antibody IgG, CSF
Also known as: AMPHI CSF
Use
The Amphiphysin Antibody IgG, CSF test is primarily used in individuals with conditions such as stiff-person syndrome, paraneoplastic encephalomyelitis (PEM), and sensory neuronopathy (SN). It aids in the diagnosis of occult tumors, recurrence of tumors, or the presence of a second tumor. Amphiphysin antibodies are present in about 5 percent of patients with stiff-person syndrome and can be found variably in other paraneoplastic neurological syndromes (PNS). The antibody is closely associated with small-cell lung cancer and breast tumors.
Special Instructions
Not provided.
Limitations
This test has not been cleared or approved by the U.S. Food and Drug Administration. It is performed in a CLIA-certified laboratory and intended for clinical purposes. The presence of amphiphysin antibodies is not solely indicative of a specific disease, and results should be interpreted within the context of a comprehensive clinical evaluation.
New York Approved
Methodology
Immunoassay (Western Blot)
Biomarkers
Amphiphysin
Antibody
LOINC Codes
- 57750-2 - Amphiphysin Ab CSF Ql IB
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1 mL
Minimum Volume
0.60 mL
Container
ARUP Standard Transport Tube
Storage Instructions
Refrigerated.
Causes for Rejection
Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |
Other tests from different labs that may be relevant